Joseph Paul Antonios, MD/PhD
Hospital ResidentCards
About
Research
Publications
2024
O14 One-year safety of treating communicating hydrocephalus with the eShunt® implant
Lylyk P, Matouk C, Riina H, Siddiqui A, Lylyk I, Bleise C, Scrivano E, Lylyk P, Antonios J, Beneduce B, Levy E, Heilman C, Malek A. O14 One-year safety of treating communicating hydrocephalus with the eShunt® implant. 2024, a9.1-a9. DOI: 10.1136/jnis-2024-esmint.14.Peer-Reviewed Original ResearchHigher proceduralist stroke thrombectomy volume is associated with reduced inpatient mortality.
Koo A, Renedo D, Ney J, Amllay A, Kanzler M, Stogniy S, Alawieh A, Sujijantarat N, Antonios J, Al Kasab S, Malhotra A, Hebert R, Matouk C, de Havenon A. Higher proceduralist stroke thrombectomy volume is associated with reduced inpatient mortality. Journal Of NeuroInterventional Surgery 2024, jnis-2024-022021. PMID: 39214687, DOI: 10.1136/jnis-2024-022021.Peer-Reviewed Original ResearchIn-hospital deathIn-hospital mortalityAcute ischemic strokeCut-pointsAbsolute risk of deathAssociated with lower oddsState Inpatient DatabasesFlorida State Inpatient DatabaseIn-hospital moralityRates of in-hospital mortalityDiagnosis of acute ischemic strokePrimary study outcomeRisk of deathStroke careOptimal cut-pointAssociated with reduced inpatient mortalityEndovascular thrombectomyRetrospective cohort studyLower oddsPotential confoundersAbsolute riskAcute ischemic stroke patientsInpatient mortalityCohort studyInpatient DatabaseO-035 Higher endovascular thrombectomy procedural volume is associated with reduced inpatient mortality
Koo A, Renedo D, Ney J, Amllay A, Kanzler M, Stogniy S, Nowicki K, Alawieh A, Sujijantarat N, Antonios J, Al Kasab S, Hebert R, Matouk C, de Havenon A. O-035 Higher endovascular thrombectomy procedural volume is associated with reduced inpatient mortality. 2024, a27.2-a28. DOI: 10.1136/jnis-2024-snis.35.Peer-Reviewed Original ResearchO-037 One-year follow-up of the eShunt® System for the treatment of normal pressure hydrocephalus
Lylyk P, Matouk C, Siddiqui A, Riina H, Lylyk I, Bleise C, Scrivano E, Lylyk P, Antonios J, Beneduce B, Levy E, Heilman C, Malek A. O-037 One-year follow-up of the eShunt® System for the treatment of normal pressure hydrocephalus. 2024, a29.1-a29. DOI: 10.1136/jnis-2024-snis.37.Peer-Reviewed Original ResearchP-031 One-year safety of the eShunt® implant used in the treatment of communicating hydrocephalus
Lylyk P, Matouk C, Siddiqui A, Riina H, Lylyk I, Bleise C, Scrivano E, Lylyk P, Antonios J, Beneduce B, Levy E, Heilman C, Malek A. P-031 One-year safety of the eShunt® implant used in the treatment of communicating hydrocephalus. 2024, a78.1-a78. DOI: 10.1136/jnis-2024-snis.103.Peer-Reviewed Original ResearchAuthor Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Everson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 4800. PMID: 38839763, PMCID: PMC11153605, DOI: 10.1038/s41467-024-48995-7.Peer-Reviewed Original ResearchTLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Everson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 3882. PMID: 38719809, PMCID: PMC11078958, DOI: 10.1038/s41467-024-48073-y.Peer-Reviewed Original ResearchConceptsAutologous tumor lysate-pulsed dendritic cellCD8+ T cellsT cellsPoly-ICLCTLR agonistsMalignant gliomasTumor lysate-pulsed dendritic cellsRandomized phase II trialCD4+ T cellsRandomized phase II clinical trialInterferon responsePhase II clinical trialPoly-ICLC treatmentDendritic cell vaccinesPD-1 expressionPhase II trialInterferon responsive gene expressionSystemic immune responsesImmune cell activationII clinical trialsInduction of interferon-inducible genesDelay disease progressionInterferon gene expressionInterferon-inducible genesPD-1Use of a dedicated open transcarotid access system for neurovascular disease
Sujijantarat N, Renedo D, Antonios J, Koo A, Amllay A, Nowicki K, Cord B, Hebert R, de Havenon A, Sheth K, Petersen N, Matouk C. Use of a dedicated open transcarotid access system for neurovascular disease. Journal Of NeuroInterventional Surgery 2024, jnis-2024-021599. PMID: 38719442, DOI: 10.1136/jnis-2024-021599.Peer-Reviewed Original ResearchExtracranial carotid stenosisTranscarotid artery revascularizationNeurovascular diseasesCarotid stenosisDatabase of consecutive patientsNeurovascular pathologyTreatment of neurovascular diseasesAccess-related complicationsTreatment of neurovascular pathologiesOff-label useCarotid flow reversalConsecutive patientsRetrospective reviewIntracranial atherosclerotic diseasePeriprocedural complicationsEndovascular treatmentArtery revascularizationProcedural characteristicsArterial sheathCarotid diseaseAcademic centersIntracranial aneurysmsPatientsTranscarotid approachTransradial approachAngiographic evidence of an inadvertent cannulation of the marginal sinus following central line migration: illustrative case
Amllay A, Owolo E, Nowicki K, Sujijantarat N, Koo A, Antonios J, Renedo D, Matouk C, Hebert R. Angiographic evidence of an inadvertent cannulation of the marginal sinus following central line migration: illustrative case. Journal Of Neurosurgery Case Lessons 2024, 7: case23607. PMID: 38684119, PMCID: PMC11058405, DOI: 10.3171/case23607.Peer-Reviewed Original ResearchCentral venous catheterInternal jugular veinCatheter tip migrationTip migrationMalpositioned cathetersAbsence of contrast extravasationSinus cannulationTriple-lumen central venous catheterAortic valve replacementInadvertent cannulationCatheter malpositionContrast extravasationValve replacementSigmoid sinusImprove patient outcomesPosterior fossaEndovascular managementSevere complicationsVenous cathetersWeeks postinsertionPrompt managementAngiographic evidenceCatheter exchangeReduce morbidityInterventional suiteThe eShunt® System: A Novel Minimally Invasive CSF Shunting System for the Treatment of Idiopathic Normal Pressure Hydrocephalus (P10-4.014)
Lylyk P, Matouk C, Siddiqui A, Riina H, Lylyk I, Bleise C, Scrivano E, Lylyk P, Antonios J, Beneduce B, Levy E, Heilman C, Malek A. The eShunt® System: A Novel Minimally Invasive CSF Shunting System for the Treatment of Idiopathic Normal Pressure Hydrocephalus (P10-4.014). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206181.Peer-Reviewed Original Research